CagriSema Beats Tirzepatide in Head-to-Head Phase 3 as FDA Decision Nears

What Happened

Novo Nordisk has reported topline phase 3 results for once-weekly CagriSema, a co-formulation of the long-acting amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, presented at the company's Capital Markets Day on 21 September 2026.

• In REIMAGINE 5, a head-to-head trial in adults with type 2 diabetes and obesity, CagriSema delivered average weight loss of 12.4% at week 60, versus 9.1% for tirzepatide at the 5 mg strength.
• Blood-sugar control was statistically non-inferior, with average HbA1c reductions of 1.71% for CagriSema versus 1.67% for tirzepatide.
• In REDEFINE 9, an obesity trial, CagriSema produced 21% average weight loss at week 68 against 2% for placebo, meeting the primary superiority endpoint.
• Secondary measures in REDEFINE 9 improved as well, including systolic blood pressure, waist-to-height ratio, and fasting lipid profile.

The company described the candidate as generally well tolerated across both trials, with a safety profile consistent with previous studies. The announcement is a rebound for the program, which had trailed Eli Lilly's tirzepatide product in an earlier head-to-head trial reported in February 2026. Novo Nordisk has a weight-management application for CagriSema on file with the FDA, with a decision expected in the fourth quarter of 2026.

Who Is Affected

• Adults with obesity or type 2 diabetes, who stand to gain a third mechanistic option alongside single GLP-1 and dual GIP/GLP-1 agonists.
• Clinical researchers running incretin trials, who now have the first phase 3 benchmark pairing an amylin analog with a GLP-1 against a dual agonist.
• Compounding and gray-market sellers, whose unapproved copies face a rising efficacy bar — and heightened regulatory attention — as approved next-generation options widen the gap.
• Payers and clinicians, who will need to weigh a new co-formulation against established tirzepatide efficacy, cost, and tolerability data.

Timeline

• February 2026: An earlier head-to-head trial favored tirzepatide over CagriSema, raising questions about the candidate's competitiveness.
• 21 September 2026: Novo Nordisk releases REIMAGINE 5 and REDEFINE 9 topline results showing superior weight loss versus both tirzepatide and placebo.
• Q4 2026: Expected FDA decision on the CagriSema weight-management application.

What This Means for Researchers

The REIMAGINE 5 result is the strongest controlled evidence yet that combining amylin and GLP-1 receptor agonism can outperform dual GIP/GLP-1 agonism on body weight. For peptide scientists, three points stand out:

• Receptor combination strategy matters. Adding an amylin analog to a GLP-1 produced a differentiated weight-loss profile without sacrificing glycemic control.
• Head-to-head designs are now the standard. Comparator trials, not placebo arms, will increasingly decide market positioning for incretin candidates.
• Post-marketing data will be decisive. If approved, real-world tolerability and durability — and the identity and purity of any compounded copies circulating in research channels — will shape the follow-up research agenda.

How to Verify Your Peptides

CagriSema is not an approved product, so anything sold to researchers under that name today is unapproved and unverified. If your lab handles incretin compounds:

• Follow our semaglutide testing and purity guide
• Use our tirzepatide HPLC testing reference
• See our overview of trusted third-party peptide testing labs

Safe Alternatives

For researchers evaluating the incretin landscape through vetted sources:

• Compare compound profiles on our semaglutide and tirzepatide reference pages
• Read our head-to-head analysis in semaglutide vs. tirzepatide
• Browse independently reviewed suppliers on our vendors directory

Sources

PepsReview Editorial, based on company announcements and industry reports, September 2026.